US FDA approves Menveo in a new single-vial presentation to help ... - GSK
WEBOct 17, 2022 · The Menveo one-vial presentation now comes in a ready to use single vial giving healthcare providers a more convenient option. The Menveo one-vial presentation …
Discover MENVEO | MENVEO [Meningococcal (Groups A, C, Y and …
WEBMENVEO is a vaccine indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135 in individuals 2 months through 55 years of age. MENVEO does not …
Novartis Receives FDA Approval of Menveo (R), a Vaccine to …
WEBFeb 22, 2010 · FDA approval of Menveo was based on a Phase III head-to-head clinical trial that compared Menveo to the other US-licensed ACWY meningococcal conjugate vaccine among subjects 11 to 55 years of age.
FDA Approves Menveo Single-Vial Presentation for Disease …
WEBOct 17, 2022 · New presentation offers health care providers with a more convenient, ready-to-use immunization option for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W.
GSK’s Menveo meningococcal vaccine in new single-vial, fully …
WEBSep 24, 2024 · GSK plc (LSE/NYSE: GSK) today announced that the European Medicine Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended for use a single-vial, fully liquid presentation of Menveo (Meningococcal Group A, C, W-135 and Y conjugate vaccine, MenACWY vaccine) to help protect against invasive meningococcal disease ...
FDA expands age indication for Menveo®, first and only …
WEBAug 1, 2013 · With this expanded indication, pediatricians in the US can now offer a single vaccine to help protect infants, children and adolescents against four of the five most common serogroups that cause ...
MENVEO | FDA - U.S. Food and Drug Administration
WEBMENVEO is a vaccine indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135 in individuals 2 months through 55...
Pfizer Announces Positive Top-Line Results from Phase 3 Trial of ...
WEBSep 15, 2022 · Phase 3 trial demonstrates that the investigational pentavalent meningococcal vaccine (MenABCWY) was well-tolerated with an acceptable safety profile and immunogenicity non-inferior to Trumenba® + Menveo® for all serogroups.
WEBNew Ready-to-Use Single Vial Presentation. Menveo is a MenACWY vaccine product approved to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W. Menveo is now available in two presentations:
Single-Vial Presentation of Meningococcal Vaccine Menveo Gets …
WEBOct 17, 2022 · The FDA has approved a new ready-to-use single dose vial presentation of Menveo for active immunization against invasive meningococcal disease.